Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 26, 2024-- Sage Therapeutics, Inc. (NASDAQ: Sage) today announced that Biogen has terminated its rights under the collaboration and license agreement with Sage specific to the SAGE-324 program.

Jan 10, 2025 · No Shareholder Action Required at This Time. CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2025-- Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.

Jan 27, 2025 · Biogen, which currently holds a 10.2% stake in Sage, proposed to acquire all outstanding Sage shares it does not already own for $7.22 per share. Shares of Sage were up 5.3% at $7.48 in early trading.

Nov 27, 2020 · Biogen and Sage enter into an agreement to jointly develop and commercialize zuranolone and SAGE-324 in the U.S.; Biogen to receive exclusive license to develop and commercialize zuranolone and SAGE-324 outside of the U.S., excluding rights to zuranolone in Japan, Taiwan and South Korea; Sage Therapeutics to receive $1.525 billion in cash comprised of an upfront payment of $875 million and a ...

Jan 21, 2025 · Sage Therapeutics last week sued partner Biogen just days after receiving an unsolicited buyout offer from the pharma for nearly $470 million, according to reporting by Bloomberg Law.. The suit, filed in a Delaware court, is sealed, according to Bloomberg, but in a separate court document, Sage noted that it “is seeking preliminary injunctive relief to enforce a standstill agreement and a ...

Sep 26, 2024 · Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their...

Jan 13, 2025 · Sage Therapeutics reported that Biogen made an unsolicited offer to purchase all of the shares of the biopharmaceutical firm it doesn't already own. The bid of $7.22 per share was a 30%...

CAMBRIDGE Mass. – July 24, 2024 – Sage Therapeutics, Inc. (NASDAQ: Sage) and Biogen Inc. (NASDAQ: BIIB) announced topline results from the Phase 2 KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET).

CAMBRIDGE, Mass., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced the U.S. Food and Drug Administration (FDA) has accepted the filing of a New Drug Application (NDA) for zuranolone in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is ...

Jan 13, 2025 · Biogen has made an unsolicited offer to acquire its partner Sage Therapeutics following a year of significant challenges for the latter. The deal, which values Sage at $7.22 per share, represents a 30% premium over the company’s closing share price of $5.55 on 10 January, when Sage confirmed the receipt of the acquisition proposal.